ClinicalTrials.gg
CompletedNCT07219004Updated Oct 21, 2025

Artacent Amniotic Tissue for Treatment of Chronic Lower Extremity Diabetic Ulcers.

An interventional study of amniotic membrane in Lower Extremity Chronic Ulcers in Diabetics and Diabetic Foot Ulcer (DFU), sponsored by Tides Medical. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Tides Medical · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Mar 2023, registered Oct 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
214th of 322
30 · median 60
Started
2023
with 18 others
No phase
186 of 381
38 open now
Registered
362nd of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 214th largest by enrollment of the 322 interventional ones that give a count, is one of 19 that started in 2023, is one of 186 with no phase, and was the 362nd registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This is study is to determine if A tri-layered dehydrated human amnion/chorion/amnion composite graft would help non-healing lower extremity diabetic ulcers to heal over a 12 week time period.

Read the detailed description

This is study is to determine if A tri-layered dehydrated human amnion/chorion/amnion composite graft would help non-healing lower extremity diabetic ulcers to heal over a 12 week time period. During this trial the patient will undergo a screening period where SOC is used to see if the patient will respond and heal > 20% of the surface area in 2 weeks. if the patient can not heal more than 20% in two week the patient then will receive a trial-layered human amnion/chorion/amnion composite graft weekly for 12 week and precent wound area reduction and complete wound healing will be recorded.

03

Conditions studied

  • Lower Extremity Chronic Ulcers in Diabetics
  • Diabetic Foot Ulcer (DFU)

Keywords

  • Diabetic Foot Ulcers
  • Chronic foot ulcers
  • Plantar Ulcers
  • Lower Extremity Ulcers
  • Amniotic Tissues
  • HCT/P
  • 361 products
  • Q4190
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be eligible to participate in the study if all the following conditions exist:

Potential subjects are required to meet all the following criteria for enrollment into the study.

  1. Subjects must be at least 18 years of age or older,
  2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.
  3. At entry subjects must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the MolecuLight Imaging HCT/P 361 .
  4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.
  5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
  6. The target ulcer must be full thickness without exposed bone.
  7. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:

    1. ABI between 0.7 and ≤ 1.3;
    2. TBI ≥ 0.6;
    3. TCOM ≥ 40 mmHg;
    4. PVR: biphasic.
  8. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
  9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment.
  10. The subject must consent to using the prescribed off-loading method for the duration of the study.
  11. The subject must agree to attend the weekly study visits required by the protocol.
  12. The subject must be willing and able to participate in the process.

Exclusion criteria

Exclusion Criteria:

  • Subjects will be excluded from participation in the study if any of the following conditions exist:

    1. A subject known to have a of \< 6 months is excluded.
    2. The subject is excluded if the target ulcer is not secondary to diabetes.
    3. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded.
    4. If there is evidence of osteomyelitis complicating the target ulcer, the subject is excluded.
    5. A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
    6. A subject receiving (including systemic at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded.
    7. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted.
    8. A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer.
    9. If a subject has (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit he/she is excluded.
    10. The subject is excluded if the surface area measurement of the Target ulcer decreases by 20% or more during the 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the subject received SOC.
    11. A Subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded.
    12. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded.
    13. A potential subject with end stage renal disease requiring dialysis is excluded.
    14. A subject who participated in a clinical trial involving treatment with an product within the previous 30 days is excluded.
    15. A subject who in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments is excluded.
    16. A Subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Artacent-AC

    Artacent AC®is a HCT/P regulated solely as a "361 Product" and meets all criteria in 21 CFR 1271.10(a). The amnion and chorion layers are harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean the amniotic and chorion membranes. A Tri-Layered Amniotic Membrane (TLAM) is then formed by adding two outer layers of amnion with the stromal sides facing outward, separated by a middle chorion layer. TLAM is dried and cut into various sizes, packaged, and terminally sterilized. Artacent AC, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers as a wound cover.

    Other: amniotic membrane

Interventions

  • Otheramniotic membrane

    The intervention is a trial-layer human amnion/chorion/amnion composite graft

    Also known as: Chorion, Q4190, Amnion

06

What researchers measure

Primary outcomes

  1. Rate of wound closure by percent of complete epithelialization

    complete wound closure measured by 100% epithelialization

    Time frame: 12 weeks

Secondary outcomes

  1. Percent area reduction

    Precent of the wound which has been re-epithelialized

    Time frame: 12 weeks

07

Study locations

5 sites
  • Three Rivers Wound and Hyperbaric Center
    North Port, Florida 34289, United States
  • Serena Group Reseach Center
    Buffalo, New York 14203, United States
  • Serena Group
    Monroeville, Pennsylvania 15146, United States
  • The Serena Group Austin Research Center
    Austin, Texas 78701, United States
  • El Campo Memorial Advanced Wound Care Clinic
    El Campo, Texas 77437, United States
08

References and documents

Individual participant data

Plan to share: No — Propritary study design

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Sep 2023, 6 months.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 6 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2025
First posted
Oct 21, 2025
StartActual
Mar 3, 2023
Primary completionActual
Sep 27, 2023
CompletionActual
Sep 27, 2023
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219004
Lead sponsor
Tides Medical
Collaborators
Serena Group
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Mar 3, 2023
Primary completion
Sep 27, 2023
Completion
Sep 27, 2023
Last update
Oct 21, 2025

Study contacts

Thomas Serena, MD
principal investigator · Serena Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion